Endologix has announced that Vaseem Mahboob, chief financial officer (CFO), will be departing the company effective 1 July 2020 to become CFO of a private global healthcare company. Cindy Pinto, vice president, Financial Planning & Analysis, will assume the role of interim CFO in addition to her current responsibilities, and Endologix has initiated a [...]
The FDA has issued a new safety communication about Type III endoleaks with AFX endovascular grafts (Endologix). According to the safety communication, there may be a higher risk of Type III endoleaks with the use of AFX with Duraply and with AFX2. The FDA reports that this communication is based on a review of [...]
Endologix has received Investigational Device Exemption (IDE) approval from the FDA to commence a new pivotal study to evaluate the safety and effectiveness of the its chimney endovascular aneurysm sealing system (ChEVAS) for the endovascular treatment of complex abdominal aortic aneurysms. A press release reports that the ChEVAS system is an endovascular abdominal aortic [...]
Source: BIBA MedTech Aortic Segmentation Monitor Endologix has announced that the CE mark for the Nellix endovascular aneurysm sealing (EVAS) system has been reinstated. The CE mark for the system was suspended on 22 January and now it that has been reinstated, Nellix will be made available for use at approved centres [...]